Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Autor: Blumenthal, GM, Bunn, PA, Chaft, JE, McCoach, CE, Perez, EA, Scagliotti, GV, Carbone, DP, Aerts, HJWL, Aisner, DL, Bergh, J, Berry, DA, Jarkowski, A, Botwood, N, Cross, DAE, Diehn, M, Drezner, NL, Doebele, RC, Blakely, CM, Eberhardt, WEE, Felip, E, Gianni, L, Keller, SP, Leavey, PJ, Malik, S, Pignatti, F, Prowell, TM, Redman, MW, Rizvi, NA, Rosell, R, Rusch, V, de Ruysscher, D, Schwartz, LH, Sridhara, R, Stahel, RA, Swisher, S, Taube, JM, Travis, WD, Keegan, P, Wiens, JR, Wistuba, II, Wynes, MW, Hirsch, FR, Kris, MG

Publikováno v: Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::2aaad27ec3457b061c95dece9d1928ac
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5308

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.

Autor: Caswell DR; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. deborah.caswell@crick.ac.uk., Gui P; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Mayekar MK; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Law EK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA., Pich O; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Bailey C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Boumelha J; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Kerr DL; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Blakely CM; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Manabe T; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Martinez-Ruiz C; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Bakker B; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., De Dios Palomino Villcas J; Core Research Laboratory, ISPRO, Florence, Italy., I Vokes N; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dietzen M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Angelova M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Gini B; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Tamaki W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Allegakoen P; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Wu W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Humpton TJ; p53 and Metabolism Laboratory, The Francis Crick Institute, London, UK.; CRUK Beatson Institute, Glasgow, UK.; Glasgow Caledonian University, Glasgow, UK., Hill W; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Tomaschko M; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Lu WT; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Haderk F; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Al Bakir M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Nagano A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Gimeno-Valiente F; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., de Carné Trécesson S; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Vendramin R; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Barbè V; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Mugabo M; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Weeden CE; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Rowan A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., McCoach CE; Genentech Inc, South San Francisco, CA, USA., Almeida B; The Roger Williams Institute of Hepatology, Foundation for Liver Research, London, UK.; Faculty of Life Sciences & Medicine, King's College London, London, UK., Green M; Experimental Histopathology, The Francis Crick Institute, London, UK., Gomez C; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Nanjo S; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Barbosa D; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Moore C; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Przewrocka J; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Black JRM; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Grönroos E; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Suarez-Bonnet A; Experimental Histopathology, The Francis Crick Institute, London, UK.; Department of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK., Priestnall SL; Experimental Histopathology, The Francis Crick Institute, London, UK.; Department of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK., Zverev C; Biological Research Facility, The Francis Crick Institute, London, UK., Lighterness S; Biological Research Facility, The Francis Crick Institute, London, UK., Cormack J; Biological Research Facility, The Francis Crick Institute, London, UK., Olivas V; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Cech L; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Andrews T; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Rule B; Cursorless, London, UK., Jiao Y; Novogene Europe, Cambridge, UK., Zhang X; Novogene Europe, Cambridge, UK., Ashford P; Institute of Structural and Molecular Biology, University College London, London, UK., Durfee C; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA., Venkatesan S; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Temiz NA; Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA., Tan L; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Larson LK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA., Argyris PP; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.; School of Dentistry, University of Minnesota, Minneapolis, MN, USA.; College of Dentistry, Ohio State University, Columbus, OH, USA., Brown WL; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA., Yu EA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Sutter Health Palo Alto Medical Foundation, Department of Pulmonary and Critical Care, Mountain View, CA, USA., Rotow JK; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Guha U; Thoracic and GI Malignancies Branch, NCI, NIH, Bethesda, MD, USA.; NextCure Inc., Beltsville, MD, USA., Roper N; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yu J; Biomedical Sciences Program, University of California, San Francisco, San Francisco, CA, USA., Vogel RI; Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA., Thomas NJ; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Marra A; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology IRCCS, Milan, Italy., Selenica P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Yu H; Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell College of Medicine, New York City, NY, USA., Bakhoum SF; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Chew SK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Reis-Filho JS; Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.; Department of Medical Oncology, University College London Hospitals, London, UK., Vousden KH; p53 and Metabolism Laboratory, The Francis Crick Institute, London, UK., McGranahan N; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kanu N; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Harris RS; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA.; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, USA., Downward J; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Bivona TG; Departments of Medicine and Cellular and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Chan Zuckerberg Biohub, San Francisco, CA, USA. trever.bivona@ucsf.edu., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.

Publikováno v: Nature genetics [Nat Genet] 2024 Jan; Vol. 56 (1), pp. 60-73. Date of Electronic Publication: 2023 Dec 04.

Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.

Autor: Ali M; Department of Pharmacology and Cancer Biology and Duke Cancer Institute, Duke University, Durham, NC 27710, USA., Lu M; Department of Pharmacology and Cancer Biology and Duke Cancer Institute, Duke University, Durham, NC 27710, USA., Ang HX; Department of Pharmacology and Cancer Biology and Duke Cancer Institute, Duke University, Durham, NC 27710, USA., Soderquist RS; Department of Pharmacology and Cancer Biology and Duke Cancer Institute, Duke University, Durham, NC 27710, USA., Eyler CE; Department of Pharmacology and Cancer Biology and Duke Cancer Institute, Duke University, Durham, NC 27710, USA., Hutchinson HM; Department of Pharmacology and Cancer Biology and Duke Cancer Institute, Duke University, Durham, NC 27710, USA., Glass C; Department of Pathology, Duke University, Durham, NC 27710, USA., Bassil CF; Department of Pharmacology and Cancer Biology and Duke Cancer Institute, Duke University, Durham, NC 27710, USA., Lopez OM; Department of Pharmacology and Cancer Biology and Duke Cancer Institute, Duke University, Durham, NC 27710, USA., Kerr DL; Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA., Falcon CJ; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA., Yu HA; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA., Hata AN; Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA., Blakely CM; Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA., McCoach CE; Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA., Bivona TG; Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA., Wood KC; Department of Pharmacology and Cancer Biology and Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2022 Mar 30; Vol. 14 (638), pp. eabc7480. Date of Electronic Publication: 2022 Mar 30.

In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"

Autor: Thomas NJ; Division of Medical Oncology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California., Myall NJ; Division of Oncology, Department of Medicine, Stanford University, Stanford, California., Sun F; Division of Medical Oncology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California., Patil T; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado., Mushtaq R; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado., Yu C; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Sinha S; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Pollom EL; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California., Nagpal S; Department of Neurology, Stanford University, Stanford, California., Camidge DR; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado., Rusthoven CG; Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado., Braunstein SE; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Wakelee HA; Division of Oncology, Department of Medicine, Stanford University, Stanford, California., McCoach CE; Division of Hematology/Oncology, University of California San Francisco, San Francisco, California; Genentech Inc., South San Francisco, California. Electronic address: caroline.mccoach@ucsf.edu.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Feb; Vol. 17 (2), pp. e12-e14.

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.

Autor: Subbiah V; The University of Texas, MD Anderson Cancer Center, Houston, Texas. vsubbiah@mdanderson.org., Gainor JF; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Oxnard GR; Dana-Farber Cancer Institute, Boston, Massachusetts., Tan DSW; National Cancer Centre Singapore, Duke-NUS Medical School, Singapore., Owen DH; The Ohio State University, Columbus, Ohio., Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Loong HH; The Chinese University of Hong Kong, Hong Kong, PR China., McCoach CE; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Weiss J; University of North Carolina, Chapel Hill, North Carolina., Kim YJ; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Gyeonggi-do, Republic of Korea., Bazhenova L; University of California, San Diego Moores Cancer Center, San Diego, California., Park K; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Daga H; Osaka City General Hospital, Osaka, Japan., Besse B; Institut Gustav Roussy, Villejuif, France; Paris-Saclay University, Orsay, France., Gautschi O; University of Berne and Cantonal Hospital of Lucerne, Lucerne, Switzerland., Rolfo C; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.; Center for Thoracic Oncology, Tisch Cancer Institute Mount Sinai Medical System- Icahn School of Medicine, Mount Sinai, New York, New York., Zhu EY; Loxo Oncology, a subsidiary of Eli Lilly and Company, Indianapolis, Indiana., Kherani JF; Loxo Oncology, a subsidiary of Eli Lilly and Company, Indianapolis, Indiana., Huang X; Loxo Oncology, a subsidiary of Eli Lilly and Company, Indianapolis, Indiana., Kang S; Eli Lilly and Company, Indianapolis, Indiana., Drilon A; Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Aug 01; Vol. 27 (15), pp. 4160-4167. Date of Electronic Publication: 2021 Jun 04.